Tag: Dupixent
Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...
Majority of patients achieved histological disease remission in 16 weeks.
FDA Approves First Treatment for Eosinophilic Esophagitis (EoE), a Chronic Immune...
EoE is a chronic inflammatory disorder in which eosinophils, a type of white blood cell, are found in the tissue of the esophagus.
Dupixent (dupilumab) Study Shows Significant Improvement in Eosinophilic Esophagitis Signs and...
Phase 3 trial in (EoE) to show a significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older
FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...
Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...
Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...
Study scheduled to commence next week.
Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...
"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."
Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy
More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.
